Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia

Vancomycin has been a key antibiotic agent for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. However, little is known about the relationship between vancomycin MIC values at the higher end of the susceptibility range and clinical outcomes. The aim of this study was...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Park, So-Youn, Oh, In-Hwan, Lee, Hee-Joo, Ihm, Chun-Gyoo, Son, Jun Seong, Lee, Mi Suk, Kim, Mi-Na
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2013
Gaiak:
Susceptibility
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3811271/
https://ncbi.nlm.nih.gov/pubmed/23979741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01137-13
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak